EN DE
Watch Curocell for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Curocell (372320) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Curocell stock KRW 15,492, price KRW 22,250, that is 30.4% below the price, quality 30 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

C Curocell logo Thin data Nov 10, 2026

Curocell

372320 · KQ
Expensive, weak quality

Our calculation puts a fair price 30% below what the stock costs today.

Low debt
Mixed vs. peers (4/8)
Fair value 15,492 KRW · Overvalued
Quality 30/100
Negative free cash flow
Narrow moat 3/100 · thin data
Thin data
Estimate
Watch Curocell for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

65,000 KRW 19,580 KRW Fair Value 15,492 KRW Nov 2023 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

36‑month range 19,580 KRW – 65,000 KRW · fair‑value band 11,619 KRW – 19,364 KRW · the 22,250 KRW price screens above the 15,492 KRW fair value. As of Nov 10, 2026.

Follow Curocell in your weekly email

Every Wednesday you see whether Curocell is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Curocell Inc., a cell gene therapy development company, engages in the development and manufacturing of pharmaceuticals.

Show moreShow less

It provides research and development services; and OVercome Immune Suppression (OVIS), a proprietary platform technology designed to get away from exhaustion induced by immune checkpoint receptors.

The company is also involved in the development of CD19 CAR-T treatment, blood cancer CAR-T, solid cancer CAR-T, and allogeneic CAR-T. Curocell Inc. was founded in 2016 and is headquartered in Daejeon, South Korea.

Stock analysis

Curocell (372320) currently trades at 22,250 KRW, while our estimate is 15,492 KRW, 30% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 11,619 KRW (bear) to 19,364 KRW (bull), the price of 22,250 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Curocell reported revenue of 0 KRW in FY2024 versus 0 KRW in FY2022. Reported net income was −46.3B KRW in FY2025.

Key figures

Market cap 350B KRW (≈ $263M) Micro · EPS (TTM) −3,383 KRW · Return on equity −101% · Return on assets (EBIT) −31.3% (5-year average) · Free cash flow −32.2B KRW · Net debt 44.6B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 3 out of 100 (low confidence).

What moves the price

The share trades about 66% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −30%, 372320 screens richer than that median.

Fair Value

Bear 11,619 KRW Fair Value 15,492 KRW Bull 19,364 KRW
Price 22,250 KRW · Downside -30.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 8
Debt, balance sheet and risk of trouble
Investment 62
Does it invest with discipline instead of growing at any price?
Low Volatility 38
How calm the share price moves, does not count
Price momentum 9
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 66
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

372320 screens overvalued: fair value 30% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Curocell with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −30.4% · Below median
Profitability
Return on assets −42.2% · Below median
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.05× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 372320
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 372320
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 372320
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 372320
argenx SE ARGX $971.55 $908.40 −7% vs 372320
CSL Limited CSL A$201.68 A$181.40 −10% vs 372320
Moderna, Inc MRNA $250.83 $158.70 −37% vs 372320
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 372320
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 372320
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 372320

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Curocell: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Curocell Fair Value". https://www.fairvalue-calculator.com/stock/372320

Frequently asked questions

Is Curocell (372320) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 15,492 KRW versus a price of 22,250 KRW, about 30% lower (overvalued).
What is the fair value of 372320?
Our estimate for Curocell is 15,492 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 22,250 KRW.
What is the quality score of 372320?
Curocell has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Curocell (372320)?
Our calculated price target is the estimate of 15,492 KRW (as of Nov 10, 2026). Cautious scenario 11,619 KRW, optimistic scenario 19,364 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Curocell stock forecast for 2026?
Our estimate puts fair value at 15,492 KRW, about 30% lower versus a price of 22,250 KRW (overvalued). Cautious scenario 11,619 KRW, optimistic scenario 19,364 KRW. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Curocell (372320)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Curocell it is 15,492 KRW per share (as of Nov 10, 2026), against a price of 22,250 KRW.
Is Curocell stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 372320 trades above its calculated fair value: price 22,250 KRW, fair value 15,492 KRW, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 372320?
No. The price is what the market pays today (22,250 KRW); the fair value is what the company's own numbers justify (15,492 KRW). For Curocell the two are 6,758 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Curocell worth?
The market values Curocell at about 350B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 22,250 KRW; our models calculate a fair value of 15,492 KRW per share.
What do the bullish and bearish scenarios say about 372320?
Our models span a range for Curocell: cautious scenario 11,619 KRW, base 15,492 KRW, optimistic 19,364 KRW per share (as of Nov 10, 2026, price 22,250 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Curocell (372320)?
Balance-sheet figures for Curocell (as of Nov 10, 2026): return on equity −101.1%. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is 372320 from its 52-week high?
Curocell trades at 22,250 KRW, about 66% below its 52-week high of 65,000 KRW and 7% above the low of 20,850 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 15,492 KRW is for.
Which stocks are comparable to Curocell?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Curocell stock attractive at the current price?
The data as of Nov 10, 2026: price 22,250 KRW, calculated fair value 15,492 KRW (−30%), Quality Score 30/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Curocell itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Curocell (372320)?
The closing price on Nov 10, 2026 was 22,250 KRW. Our estimate is 15,492 KRW, about 30% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Curocell right now?
The price sits above even our optimistic bull case (19,364 KRW). The favourable scenario is already priced in. Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Curocell

How large is the market capitalisation of Curocell (372320)?
The market capitalisation of Curocell is 350B KRW (≈ $263M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Curocell (372320)?
Earnings per share at Curocell are −3,383 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Curocell (372320)?
The return on equity (ROE) of Curocell is −101% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Curocell (372320)?
On an EBIT basis the return on assets of Curocell is −31.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Curocell (372320) generate?
The free cash flow of Curocell is −32.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Curocell (372320) carry?
The net debt of Curocell is 44.6B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Curocell in the live analysis

One click puts Curocell on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.